The biotechnology company Celera has generated controversy by reporting that it will sequence the human genome in 3 years with the aid of 230 new high-throughput DNA sequencing machines, well before the efforts of the Human Genome Project are slated to be competed. Now J. C. Mullikin and A. A. McMurray report their evaluation of this sequencer, the ABI 3700 from Perkin-Elmer.
No takes yet. Share an insight, caveat, or question.
Mullikin et al. (1999) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: